PCSK9 Polyclonal antibody

• Featured Product
• KD/KO Validated

PCSK9 Polyclonal Antibody for IHC, WB, ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human, rat and More (1)

Applications

WB, IP, IHC, IF, ELISA

Conjugate

Unconjugated

Publications

36

Reviews (1)

Cat no : 55206-1-AP

Synonyms

FH3, HCHOLA3, LDLCQ1, NARC 1, NARC1, PC9, PCSK9, Proprotein convertase 9

---

Validation Data Gallery

• 

  WB analysis using 55206-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 55206-1-AP (PCSK9 antibody) at dilution of 1:1500 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 55206-1-AP

  Rat brain tissue were subjected to SDS PAGE followed by western blot with 55206-1-AP (PCSK9 antibody) at dilution of 1:1500 incubated at room temperature for 1.5 hours.

• 

  WB analysis of HepG2 using 55206-1-AP

  HepG2 cells were subjected to SDS PAGE followed by western blot with 55206-1-AP (PCSK9 antibody) at dilution of 1:600 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human colon cancer using 55206-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 55206-1-AP (PCSK9 antibody) at dilution of 1:500 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human colon cancer using 55206-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 55206-1-AP (PCSK9 antibody) at dilution of 1:500 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human colon cancer using 55206-1-AP

  Immunohistochemical analysis of paraffin-embedded human colon cancer tissue slide using 55206-1-AP (PCSK9 antibody) at dilution of 1:500 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Tested Applications

• Positive WB detected in: COLO 320 cells, rat brain tissue, HepG2 cells, SMMC-7721 cells
• Positive IHC detected in: human colon cancer tissue; Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

• Western Blot (WB): WB : 1:500-1:3000
• Immunohistochemistry (IHC): IHC : 1:250-1:1000

Sample-dependent, check data in validation data gallery

Published Applications

• KD/KO: See 7 publications below
• WB: See 30 publications below
• IHC: See 12 publications below
• IF: See 3 publications below
• IP: See 1 publications below

Product Information

55206-1-AP targets PCSK9 in WB, IP, IHC, IF, ELISA applications and shows reactivity with human, rat samples.

• Tested Reactivity: human, rat
• Cited Reactivity: human, rat, hamster
• Host / Isotype: Rabbit / IgG
• Class: Polyclonal
• Type: Antibody
• Immunogen: Peptide
• Full Name: proprotein convertase subtilisin/kexin type 9
• Calculated molecular weight: 74 kDa
• Observed molecular weight: 58-62 kDa, 72-78 kDa
• GenBank accession number: NM_174936
• Gene symbol: PCSK9
• Gene ID (NCBI): 255738
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Antigen affinity purification
• Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
• Storage Conditions: Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20^oC storage. 20ul sizes contain 0.1% BSA.

Background Information

Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a crucial protein governing the circulating levels of low density lipoprotein-cholesterol (LDL-C), by virtue of its pivotal role in the degradation of the LDL receptor (LDLR). PCSK9 is expressed in the kidney and lung. It is synthesized as a 72 kDa immature precursor that undergoes autocatalytic cleavage in the endoplasmic reticulum to generate a 63 kDa mature protein. The cleaved N-terminal fragment remains associated with the mature protein and is necessary for its secretion, allowing it to circulate in the blood. The ability of PCSK9 to regulate a diverse group of cell-surface proteins hinted that it might also be able to influence additional membrane proteins that are important in anti-tumour immune responses. Targeting PCSK9 to treat cancer is also attractive because two neutralizing antibodies against it, evolocumab and alirocumab, have already been approved for human clinical use to lower cholesterol levels. (PMID: 30522786, PMID: 22493497)

Publications

Species	Application	Title
human,mouse	WB	Nature; Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer.; Authors - Xinjian Liu ; KO Validated
mouse	WB,IHC,IF	J Nanobiotechnology; Evolocumab loaded Bio-Liposomes for efficient atherosclerosis therapy; Authors - Zhenxian Li
human,hamster	WB	Biomed Pharmacother; Berberine is a potential alternative for metformin with good regulatory effect on lipids in treating metabolic diseases; Authors - Hui-Hui Guo
human	IHC	Front Immunol; PCSK9 regulates the efficacy of immune checkpoint therapy in lung cancer; Authors - Xiang Gao
human,mouse	WB	Int J Mol Sci; Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity; Authors - Po-Wei Chen
human,rat	WB,IHC,IF	Int J Mol Sci; Renal Ischemia/Reperfusion Early Induces Myostatin and PCSK9 Expression in Rat Kidneys and HK-2 Cells.; Authors - Chiara Barisione

Reviews

The reviews below have been submitted by verified Proteintech customers who received an incentive forproviding their feedback.

---

FH

Malak (Verified Customer) (11-30-2020)

The antibody works very well in IHC staining especially at pH6 and 1/100 dilution

• Applications: Immunohistochemistry
• Primary Antibody Dilution: 1/100
• Cell Tissue Type: Hepatic tissue